These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 28918407)

  • 1. Burden of non-adherence to latent tuberculosis infection drug therapy and the potential cost-effectiveness of adherence interventions in Canada: a simulation study.
    Patel AR; Campbell JR; Sadatsafavi M; Marra F; Johnston JC; Smillie K; Lester RT
    BMJ Open; 2017 Sep; 7(9):e015108. PubMed ID: 28918407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of Testing and Treatment for Latent Tuberculosis Infection in Residents Born Outside the United States With and Without Medical Comorbidities in a Simulation Model.
    Tasillo A; Salomon JA; Trikalinos TA; Horsburgh CR; Marks SM; Linas BP
    JAMA Intern Med; 2017 Dec; 177(12):1755-1764. PubMed ID: 29049814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immigrant screening for latent tuberculosis in Norway: a cost-effectiveness analysis.
    Haukaas FS; Arnesen TM; Winje BA; Aas E
    Eur J Health Econ; 2017 May; 18(4):405-415. PubMed ID: 26970772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of latent tuberculosis infection testing and treatment with 6-week regimen among key population in rural communities in China: a decision analysis study.
    Cao X; Guo T; Xin H; Du J; Yang C; Feng B; He Y; Shen L; Di Y; Li Z; Chen Y; Liang J; Jin Q; Wang L; Gao L
    Eur J Clin Microbiol Infect Dis; 2024 May; 43(5):809-820. PubMed ID: 38383889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modeling the Cost-Effectiveness of Latent Tuberculosis Screening and Treatment Strategies in Recent Migrants to a Low-Incidence Setting.
    Dale KD; Abayawardana MJ; McBryde ES; Trauer JM; Carvalho N
    Am J Epidemiol; 2022 Jan; 191(2):255-270. PubMed ID: 34017976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Latent Tuberculosis Infection Testing Strategies for HIV-Positive Individuals in Hong Kong.
    Wong NS; Chan KCW; Wong BCK; Leung CC; Chan WK; Lin AWC; Lui GCY; Mitchell KM; Lee SS
    JAMA Netw Open; 2019 Sep; 2(9):e1910960. PubMed ID: 31490541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating the potential costs and impact of digital health technologies for tuberculosis treatment support.
    Nsengiyumva NP; Mappin-Kasirer B; Oxlade O; Bastos M; Trajman A; Falzon D; Schwartzman K
    Eur Respir J; 2018 Nov; 52(5):. PubMed ID: 30166325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of 3 months of weekly rifapentine and isoniazid compared to isoniazid monotherapy in a Canadian arctic setting.
    Pease C; Alvarez G; Mallick R; Patterson M; Finn S; Habis Y; Schwartzman K; Kilabuk E; Mulpuru S; Zwerling A
    BMJ Open; 2021 May; 11(5):e047514. PubMed ID: 33986067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of weekly text-message communication on treatment completion among patients with latent tuberculosis infection: study protocol for a randomised controlled trial (WelTel LTBI).
    van der Kop ML; Memetovic J; Patel A; Marra F; Sadatsafavi M; Hajek J; Smillie K; Thabane L; Taylor D; Johnston J; Lester RT
    BMJ Open; 2014 Apr; 4(4):e004362. PubMed ID: 24719431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening for latent and active tuberculosis infection in the elderly at admission to residential care homes: A cost-effectiveness analysis in an intermediate disease burden area.
    Li J; Yip BHK; Leung C; Chung W; Kwok KO; Chan EYY; Yeoh E; Chung P
    PLoS One; 2018; 13(1):e0189531. PubMed ID: 29293514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of 3 months of weekly rifapentine and isoniazid compared with other standard treatment regimens for latent tuberculosis infection: a decision analysis study.
    Doan TN; Fox GJ; Meehan MT; Scott N; Ragonnet R; Viney K; Trauer JM; McBryde ES
    J Antimicrob Chemother; 2019 Jan; 74(1):218-227. PubMed ID: 30295760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of a 12-dose regimen for treating latent tuberculous infection in the United States.
    Shepardson D; Marks SM; Chesson H; Kerrigan A; Holland DP; Scott N; Tian X; Borisov AS; Shang N; Heilig CM; Sterling TR; Villarino ME; Mac Kenzie WR
    Int J Tuberc Lung Dis; 2013 Dec; 17(12):1531-7. PubMed ID: 24200264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effectiveness and cost-effectiveness of screening for latent tuberculosis among migrants in the EU/EEA: a systematic review.
    Greenaway C; Pareek M; Abou Chakra CN; Walji M; Makarenko I; Alabdulkarim B; Hogan C; McConnell T; Scarfo B; Christensen R; Tran A; Rowbotham N; van der Werf MJ; Noori T; Pottie K; Matteelli A; Zenner D; Morton RL
    Euro Surveill; 2018 Apr; 23(14):. PubMed ID: 29637889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening for Latent Tuberculosis Infection in Migrants With CKD: A Cost-effectiveness Analysis.
    Campbell JR; Johnston JC; Ronald LA; Sadatsafavi M; Balshaw RF; Cook VJ; Levin A; Marra F
    Am J Kidney Dis; 2019 Jan; 73(1):39-50. PubMed ID: 30269868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accurate diagnosis of latent tuberculosis in children, people who are immunocompromised or at risk from immunosuppression and recent arrivals from countries with a high incidence of tuberculosis: systematic review and economic evaluation.
    Auguste P; Tsertsvadze A; Pink J; Court R; Seedat F; Gurung T; Freeman K; Taylor-Phillips S; Walker C; Madan J; Kandala NB; Clarke A; Sutcliffe P
    Health Technol Assess; 2016 May; 20(38):1-678. PubMed ID: 27220068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic Review, Meta-analysis, and Cost-effectiveness of Treatment of Latent Tuberculosis to Reduce Progression to Multidrug-Resistant Tuberculosis.
    Marks SM; Mase SR; Morris SB
    Clin Infect Dis; 2017 Jun; 64(12):1670-1677. PubMed ID: 28329197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Impact and Cost-Effectiveness of a Four-Month Regimen for First-Line Treatment of Active Tuberculosis in South Africa.
    Knight GM; Gomez GB; Dodd PJ; Dowdy D; Zwerling A; Wells WA; Cobelens F; Vassall A; White RG
    PLoS One; 2015; 10(12):e0145796. PubMed ID: 26717007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How much does tuberculosis cost? An Australian healthcare perspective analysis.
    Chan E; Nolan A; Denholm J
    Commun Dis Intell Q Rep; 2017 Sep; 41(3):E191-E194. PubMed ID: 29720069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting screening and treatment for latent tuberculosis infection towards asylum seekers from high-incidence countries - a model-based cost-effectiveness analysis.
    Marx FM; Hauer B; Menzies NA; Haas W; Perumal N
    BMC Public Health; 2021 Nov; 21(1):2172. PubMed ID: 34836526
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.